Exposure Therapy, d -Cycloserine, and Functional Magnetic Resonance Imaging in Patients With Snake Phobia: A Randomized Pilot Study
The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: d-Cycloserine may enhance fear extinction. The effects of d-cycloserine on human brain function are not well understood, with findings suggesting that d-cycloserine could augment exposure therapy via its effects on the neural substrates of emotional learning and extinction or by acting upon different neural pathways. The aim of this exploratory study was to investigate differences in neural response in patients receiving d-cycloserine or placebo in addition to exposure therapy. METHOD: Twenty adults with snake phobia (DSM-IV specific phobia) received 50 mg of d-cycloserine or placebo (double-blind, randomized) 1 hour prior to a single session of graded exposure therapy in an outpatient specialty clinic. One week before and after treatment, patients completed a clinical examination and snake-stimuli symptom provocation functional magnetic resonance imaging (fMRI) task (primary outcome measure). RESULTS: The d-cycloserine and placebo groups responded equally well to treatment, although the d-cycloserine patients reached the top of the exposure hierarchy more quickly (t = 2.61, P < .05). Only right dorsolateral prefrontal cortex showed an equivalent decrease in hyperactivation to snake stimuli in both groups. Compared to placebo, d-cycloserine augmentation resulted in different ventromedial prefrontal brain activation during processing of phobic stimuli, including enhanced medial orbitofrontal (F = 11.52, P = .001) and subgenual anterior cingulate activation (F = 7.41, P = .008) and normalized perigenual cingulate "deactivation" (F = 3.85, P = .05) to snakes. CONCLUSIONS: A single administration of d-cycloserine combined with exposure therapy can lead to lasting changes in ventromedial and other prefrontal cortex response to phobic stimuli. These changes are qualitatively different from those seen in patients receiving exposure therapy without d-cycloserine. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT01450306.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Phelps, E. A., Delgado, M. R., Nearing, K. I., & LeDoux, J. E. (2004) · Neuron · doi:10.1016/j.neuron.2004.08.042 · Cited by 1,753
A Bio‐Informational Theory of Emotional Imagery
Lang, P. J. (1979) · Psychophysiology · doi:10.1111/j.1469-8986.1979.tb01511.x · Cited by 1,750
LaBar, K. S., Gatenby, J. C., Gore, J. C., LeDoux, J. E., & Phelps, E. A. (1998) · Neuron · doi:10.1016/s0896-6273(00)80475-4 · Cited by 1,402
Phillips, M. L., Ladouceur, C. D., & Drevets, W. C. (2008) · Molecular Psychiatry · doi:10.1038/mp.2008.65 · Cited by 1,383
Ressler, K. J., Rothbaum, B. O., Tannenbaum, L., Anderson, P., Graap, K., Zimand, E., Hodges, L., & Davis, M. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.11.1136 · Cited by 1,063
Extinction of emotional learning: contribution of medial prefrontal cortex
Morgan, M. A., Romanski, L. M., & LeDoux, J. E. (1993) · Neuroscience Letters · doi:10.1016/0304-3940(93)90241-c · Cited by 897
Walker, D. L., Ressler, K. J., Lu, K.-T., & Davis, M. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-06-02343.2002 · Cited by 815
Morgan, M. A., & LeDoux, J. E. (1995) · Behavioral Neuroscience · doi:10.1037/0735-7044.109.4.681 · Cited by 717
Neural circuitry underlying the regulation of conditioned fear and its relation to extinction
Delgado, M. R., Nearing, K. I., LeDoux, J. E., & Phelps, E. A. (2008) · Neuron · doi:10.1016/j.neuron.2008.06.029 · Cited by 716
Significance of the insula for the evolution of human awareness of feelings from the body
(Bud) Craig, A. D. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2011.05990.x · Cited by 646
Cited by
Baldwin, D. S., Anderson, I. M., Nutt, D. J., Allgulander, C., Bandelow, B., den Boer, J. A., Christmas, D. M., Davies, S., Fineberg, N., Lidbetter, N., et al. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114525674 · Cited by 676
“…placebo-controlled studies suggest that the efficacy of exposure therapy can be enhanced through prior administration of d-cycloserine [I (PCT)] (Nave et al., 2012; Ressler et al., 2004): but not all evidence is consistent [I (PCT)] (Guastella et al., 2007), and its administration after a…”
BackgroundPharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options
Garakani, A., Murrough, J. W., Freire, R. C., Thom, R. P., Larkin, K., Buono, F. D., & Iosifescu, D. V. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.595584 · Cited by 440
Singewald, N., Schmuckermair, C., Whittle, N., Holmes, A., & Ressler, K. J. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.12.004 · Cited by 390
“, 2014; Scheeringa & Weems, 2014), specific phobia (Guastella et al., 2007; Nave et al., 2012; Ressler et al., 2004), SAD (Guastella et al.”
BackgroundMethodMataix-Cols, D., Fernández de la Cruz, L., Monzani, B., Rosenfield, D., Andersson, E., Pérez-Vigil, A., Frumento, P., de Kleine, R. A., Difede, J., Dunlop, B. W., et al. (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2016.3955 · Cited by 288
Self-citationDoes D-cycloserine enhance exposure therapy for anxiety disorders in humans? A meta-analysis
Rodrigues, H., Figueira, I., Lopes, A., Gonçalves, R., Mendlowicz, M. V., Coutinho, E. S. F., & Ventura, P. (2014) · PLoS ONE · doi:10.1371/journal.pone.0093519 · Cited by 109
“[36], one participant in the DCS group reported mild nausea during the hour following administration.”
BackgroundEnhancement of psychosocial treatment with D-cycloserine: Models, moderators, and future directions
Otto, M. W., Kredlow, M. A., Smits, J. A. J., Hofmann, S. G., Tolin, D. F., de Kleine, R. A., van Minnen, A., Evins, A. E., & Pollack, M. H. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.09.007 · Cited by 70
Self-citationd-Cycloserine as an augmentation strategy for cognitive behavioral therapy of anxiety disorders
Hofmann, S. G., Wu, J. Q., & Boettcher, H. (2013) · Biology of Mood & Anxiety Disorders · doi:10.1186/2045-5380-3-11 · Cited by 59
“, 2012 [57] Snake phobia 20 50 1 1 Exposure (1) Snake Questionnaire No overall DCS effects.”
BackgroundMcGuire, J. F., Lewin, A. B., & Storch, E. A. (2014) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2014.934677 · Cited by 57
“Similar findings for an expedited therapeutic benefit were observed among DCS-enhanced exposures for ophidiophobia (fear of snakes) as evidenced by shorter time to complete a 13-step exposure hierarchy [36], as well as enhanced therapeutic outcome after DCS-augmented subliminal exposures for subthreshold arachnophobia…”
BackgroundResultBürkner, P.-C., Bittner, N., Holling, H., & Buhlmann, U. (2017) · PLoS ONE · doi:10.1371/journal.pone.0173660 · Cited by 41
“phobia / specific phobia with 20 participants [39], three studies described the treatment of patients with agoraphobia / panic disorder with a total of 246 participants [22,23,40], eight studies including 423 patients with OCD [20,24–29,44], four studies conducted their study on 256 patients suffering from post-trauma…”
BackgroundResultTolin, D. F. (2017) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2017.08.007 · Cited by 25
Self-citationStarting from something: augmenting exposure therapy and methods of inquiry
Tuerk, P. W. (2014) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2014.14070880 · Cited by 15
A precision medicine approach to pharmacological adjuncts to extinction: A call to broaden research
King, G., Baker, K. D., Bisby, M. A., Chan, D., Cowan, C. S. M., Stylianakis, A. A., Zimmermann, K. S., & Richardson, R. (2019) · Psychopharmacology · doi:10.1007/s00213-018-4999-0 · Cited by 6
Metadata
- Authors
- Nave, A. M., Tolin, D. F., & Stevens, M. C.
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2012-09-15
- Volume
- 73
- Issue
- 09
- Pages
- 1179-1186
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2010391919
- Cited by
- 45
- References
- 27
- FWCI
- 8.68
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.